

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 5, 2025

CD8

RRID:AB_2890107

Type: Antibody

Proper Citation

(ZSGB-Bio Cat# ZA-0508, RRID:AB_2890107)

Antibody Information

URL: http://antibodyregistry.org/AB_2890107

Proper Citation: (ZSGB-Bio Cat# ZA-0508, RRID:AB_2890107)

Clonality: unknown

Antibody Name: CD8

Description: This unknown targets

Antibody ID: AB_2890107

Vendor: ZSGB-Bio

Catalog Number: ZA-0508

Record Creation Time: 20231110T031647+0000

Record Last Update: 20240725T092643+0000

Ratings and Alerts

No rating or validation information has been found for CD8.

No alerts have been found for CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](https://fdilab.sciencemag.org/).

Wang H, et al. (2024) Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. *Med (New York, N.Y.)*, 5(10), 1237.

Wang Y, et al. (2024) Pig-to-human kidney xenotransplants using genetically modified minipigs. *Cell reports. Medicine*, 5(10), 101744.

Jia D, et al. (2024) Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. *Cell*, 187(7), 1651.

Liu W, et al. (2024) An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure. *Cell reports. Medicine*, 5(3), 101448.

Wang H, et al. (2024) Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma. *Cell reports*, 43(12), 115015.

Li J, et al. (2024) Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(2), 368.

Wang X, et al. (2024) Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. *Cell*, 187(18), 4890.

Huang CX, et al. (2024) Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. *Cancer cell*, 42(12), 2082.

Duan J, et al. (2023) Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma. *Cell reports. Medicine*, 4(12), 101302.

Lin J, et al. (2023) Fas/FasL and Complement Activation are Associated with Chronic Active Epstein-Barr Virus Hepatitis. *Journal of clinical and translational hepatology*, 11(3), 540.

Li J, et al. (2023) Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. *Cancer cell*, 41(6), 1152.

Wen J, et al. (2022) Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma. *EBioMedicine*, 86, 104371.